1. Home
  2. BZH vs IMMX Comparison

BZH vs IMMX Comparison

Compare BZH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beazer Homes USA Inc.

BZH

Beazer Homes USA Inc.

SELL

Current Price

$33.46

Market Cap

890.0M

ML Signal

SELL

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$7.96

Market Cap

784.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZH
IMMX
Founded
1985
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
890.0M
784.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
BZH
IMMX
Price
$33.46
$7.96
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
★ $27.50
$24.30
AVG Volume (30 Days)
1.2M
★ 1.6M
Earning Date
11-12-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,087,739,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$16.26
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$17.83
$2.71
52 Week High
$34.54
$15.10

Technical Indicators

Market Signals
Indicator
BZH
IMMX
Relative Strength Index (RSI) 60.98 27.55
Support Level $33.07 $7.96
Resistance Level $33.98 $10.61
Average True Range (ATR) 0.06 0.59
MACD -0.02 -0.17
Stochastic Oscillator 98.15 1.73

Price Performance

Historical Comparison
BZH
IMMX

About BZH Beazer Homes USA Inc.

Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: